IP Library Granted Patent US 7,598,421
Granted Patent B2
US 7,598,421 · App. 10/983,464 · Granted Oct 6, 2009

Materials for the delivery of biologically-active material to cells

Assignee: UCL Biomedica PLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,598,421
App. No.
10/983,464
Granted
Oct 6, 2009
Kind
B2
Abstract

The invention provides a lipid of general formula (I) or (II): wherein X 1 , X 2 and R 1 to R 5 are as defined herein. Such lipids are used to form complexes with a biologically-active material such as a nucleic acid, peptide or small molecule for delivering the biologically-active material to cells. The complexes may incorporate an integrin-binding peptide and, when the biologically-active material is DNA, thereby constitute a LID complex.

Claims (48)

1. A lipid of general formula (I) or (II):

wherein

X 1 and X 2 are —O—;

R 1 and R 2 for formula I are the same or different and are straight or branched, saturated or unsaturated C 7 to C 24 hydrocarbyl groups which are unsubstituted or substituted by one or more substituents selected from the group consisting of hydroxy, halogen and OR′, wherein R′ is a C 1 to C 6 hydrocarbyl group and

R 1 and R 2 for formula II are the same or different and are straight or branched unsaturated C 7 to C 24 hydrocarbyl groups or straight or branched saturated C 18 to C 24 hydrocarbyl groups, which are unsubstituted or substituted by one or more substituents selected from the group consisting of hydroxy, halogen and OR′, wherein R′ is a C 1 to C 6 hydrocarbyl group;

R 5 is —N + (R 3 ) 2 —R 6 ;

R 6 is either:

(a) -[A-Y] n R 4 wherein:

each Y is the same or different and is —N + (R 4 ) 2 —;

each A is the same or different and is a C 1-20 alkylene group which is unsubstituted or substituted by one or more substituents selected from the group consisting of hydroxy, halogen, —OR′, —C(O)OH, —CN, —NR′R″, and —C(O)R′ wherein R′ and R″ are the same or different and are C 1-6 hydrocarbyl; and

n is an integer of from 1 to 10; or

(b) —[B—O] m B-Q wherein:

each B is the same or different and is a C 1-10 alkylene group which is unsubstituted or substituted by one or more substituents selected from the group consisting of hydroxy, halogen, —OR′, —C(O)OH, —CN, —NR′R″ and —C(O)R′ wherein R′ and R″ are the same or different and are C 1-6 hydrocarbyl;

m is an integer of from 1 to 10; and

Q is selected from the group consisting of —N + (R 3 ) 3 , —OH, —OR′, —OC(O)R′ and halogen, wherein R′ is as defined above; and

each R 3 and each R 4 is the same or different and is a straight or branched, saturated or unsaturated C 1 to C 10 hydrocarbyl group which is unsubstituted or substituted by one or more substituents selected from the group consist of hydroxy, halogen, —OR′, —C(O)OH, —CN, —NR′R″, and —C(O)R′ wherein R′ and R″ are the same or different and are C 1 to C 6 hydrocarbyl.

2. A lipid according to claim 1 wherein R 1 and R 2 are the same or different and represent a C 12-20 hydrocarbyl group.

3. A lipid according to claim 2 wherein R 1 and R 2 are the same or different and represent a C 14 , C 16 , C 18 or C 20 alkenyl group having one, two or three double bonds.

4. A lipid according to claim 3 wherein R 1 and R 2 are both C 16 or C 18 alkenyl groups having one double bond.

5. A lipid according to claim 1 wherein R 5 is —N + (R 3 ) 2 —R 5 and R 6 is —[B—O] m B-Q,

wherein:

each B is the same or different and is a C 1-6 alkylene group which is unsubstituted or substituted by one or more substituents selected from the group consisting of hydroxy, halogen, —OR′, —C(O)OH, —CN, —NR′R″ and —C(O)R′ wherein R′ and R″ are the same or different and are C 1-4 hydrocarbyl;

m is an integer of from 1 to 8; and

Q is selected from the group consisting of —N + (R 3 ) 3 , —OH and —OR′ wherein R′ is a C 1-4 alkyl group.

6. A lipid according to claim 1 , having the general formula (III):

wherein

R 1 and R 2 are the same or different and are straight or branched, saturated or unsaturated C 12-20 hydrocarbyl groups which are unsubstituted or substituted by one or more substituents selected from the group consisting of hydroxy, halogen and —OR′ wherein R′ is a C 1-6 hydrocarbyl group;

each R 3 is the same or different and is a straight or branched, saturated or unsaturated C 1-6 hydrocarbyl group which is unsubstituted or substituted by one or more substituents selected from the group consisting of hydroxy, halogen, —OR′, —COOH, —CN, —NR′R″ and —COR′ wherein R′ and R″ are the same or different and are C 1-4 hydrocarbyl;

R 6 is —[B—O] m B-Q wherein each B is the same or different and is a C 1-6 alkylene group which is unsubstituted or substituted by one or more substituents selected from the group consisting of hydroxy, halogen, —OR′, —C(O)OH, —CN, —NR′R″ and —C(O)R′ wherein R′ and R″ are the same or different and are C 1-4 hydrocarbyl; m is an integer of from 1 to 8; and Q is selected from the group consisting of —N + (R 3 ) 3 , —OH, —OR′, —OC(O)R′ and halogen wherein R′ is as defined above.

7. A lipid according to claim 1 , having the general formula (IV):

wherein

R 1 and R 2 are the same or different and are selected from the group consisting of C 12-20 alkylene groups and C 12-20 alkenylene groups;

each R 3 is the same or different and is selected from unsubstituted C 1-4 alkyl groups;

each B is the same or different and is a C 1-6 alkylene group which is unsubstituted or substituted by one or more substituents selected from the group consisting of hydroxy, halogen, —OR′, —C(O)OH, —CN, —NR′R″ and —C(O)R′ wherein R′ and R″ are the same or different and are C 1-4 hydrocarbyl;

m is an integer from 3 to 8; and

Q is selected from the group consisting of —N + (R 3 ) 3 , —OH, and —OR′ wherein R′ is an unsubstituted C 1-4 alkyl group.

8. A lipid according to claim 7 wherein R 1 and R 2 are both C 12-20 alkenylene groups having one double bond each.

9. A lipid according to claim 7 wherein each R 3 group is a methyl or ethyl group.

10. A lipid according to claim 7 wherein each B is the same or different and is an unsubstituted C 1-3 alkylene group.

11. A lipid according to claim 7 wherein m is selected from the group consisting of 3, 4, 5, 6 and 7.

12. A lipid according to claim 7 wherein Q is —OH or —OR′ wherein R′ is an unsubstituted C 1-4 alkyl group.

13. A lipid according to claim 1 , selected from the group consisting of {2,3-Di-[(Z)-octadec-9-enyloxy]-propyl}-N-(2-{2-[2-(2-hydroxy-ethoxy)-ethoxy]-ethoxy}-ethyl)-N,N-dimethylammonium bromide; {2,3-Di-[(Z)-ocatadec-9-enyloxy]-propyl}-N-{2-[2-(2-{2-[2-(2-hydroxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethyl}-N,N-dimethylammonium bromide; {2,3-Di-[(Z)-hexadec-11-enyloxy]-propyl}-N-(2-{2-[2-(2-hydroxy-ethoxy)-ethoxy]-ethoxy}-ethyl)-N,N-dimethylammonium bromide; {2,3-Di-[(Z)-hexadec-11-enyloxy]-propyl}-N-{2-[2-(2-{2-[2-(2-hydroxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethyl}-N,N-dimethylammonium bromide; and 1,4-Di(trimethylammonium)-2,2-dioleoyloxy-butane, diiodide.

14. A complex suitable for delivery of a biologically-active material to a cell, which complex comprises a lipid according to claim 1 and a biologically-active material.

15. A complex according to claim 14 wherein the biologically-active material is a nucleic acid, a peptide or a small molecule.

16. A complex according to claim 15 wherein the nucleic acid is a DNA or RNA.

17. A complex according to claim 14 which further comprises an integrin-binding peptide.

18. A process for the preparation of a complex comprising a lipid and a biologically-active material, which process comprises the step of admixing (i) a lipid according to claim 1 and (ii) a biologically-active material.

19. A process according to claim 18 , wherein an integrin-binding peptide is admixed with said lipid and said biologically-active material.

Assignments (6)
NUNC PRO TUNC ASSIGNMENT Recorded Jan 2, 2024
From: RYBOQUIN COMPANY LTD
To: NANOGENICS LIMITED
Reel/Frame 066179/0605 →
NUNC PRO TUNC ASSIGNMENT Recorded Dec 25, 2023
From: RYBOQUIN COMPANY LTD
To: NANOGENICS LIMITED
Reel/Frame 066123/0553 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 24, 2018
From: UCL BUSINESS PLC
To: RYBOQUIN COMPANY LTD
Reel/Frame 046942/0973 →
CHANGE OF NAME Recorded Aug 24, 2018
From: UCL BIOMEDICA PLC
To: UCL BUSINESS PLC
Reel/Frame 046695/0067 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 20, 2005
From: UNIVERSITY COLLEGE LONDON
To: UCL BIOMEDICA PLC
Reel/Frame 016548/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 20, 2005
From: HAILES, HELEN C.; TABOR, ALETHEA B.; WONG, JOHN B.; PILKINGTON-MIKSA, MICHAEL; HART, STEPHEN L.; HURLEY, CHRISTOPHER A.
To: UNIVERSITY COLLEGE LONDON
Reel/Frame 016548/0859 →
Priority Claims (1)
GB 0210538.5 · May 8, 2002 · national
Continuity (3)
Continuation In Part PCTGB030198500 · May 8, 2003
Provisional Application 6057627000 · Jun 2, 2004
Related Publication 20050245446A1 · Nov 3, 2005